



17 April 2020

ASX LIMITED

SomnoMed Limited ACN 003 255 221 (ASX:SOM) – successful completion of retail component of entitlement offer

SomnoMed Limited ACN 003 255 221 (**SomnoMed** or **Company**) is today pleased to announce the successful completion of the retail component (**Retail Entitlement Offer**) of its 1 for 3.24 fully underwritten accelerated non-renounceable entitlement offer (**Entitlement Offer**).

The Retail Entitlement Offer closed on Wednesday, 15 April 2020, and raised approximately \$5.8 million.

Completion of the Retail Entitlement Offer represents completion of the second stage of the Company's \$15.5 million Entitlement Offer announced on Wednesday, 25 March 2020. The first stage of the Entitlement Offer, being the \$9.7 million institutional component of the Entitlement Offer, completed on Wednesday, 25 March 2020, as announced to the market by the Company on Thursday, 26 March 2020.

The Retail Entitlement Offer provided eligible retail shareholders of the Company the opportunity to subscribe for 1 new fully paid ordinary share in the Company (**New Share**) for every 3.24 existing fully paid ordinary shares which they held in the Company as at 7.00pm (Sydney, Australia time) on Friday, 27 March 2020 (**Entitlement**), at a price of \$0.80 per New Share. Eligible retail shareholders who took up their Entitlement in full under the Retail Entitlement Offer were invited to apply for additional New Shares of up to 100% in excess of their Entitlement (**Additional New Shares**), with any scale-back at the absolute discretion of the Company. The Company confirms that all shareholders who applied for Additional New Shares of up to 100% in excess of their Entitlement will have their applications allotted in full.

The Company received valid applications from eligible retail shareholders for approximately 5.4 million New Shares (including Additional New Shares) under the Retail Entitlement Offer. The remaining approximately 1.9 million New Shares not taken up by eligible retail shareholders under the Retail Entitlement Offer will be allocated to sub-underwriters under the Retail Entitlement Offer.

Settlement of the Retail Entitlement Offer is expected to occur on Tuesday, 21 April 2020, with the New Shares and Additional New Shares expected to commence trading on the ASX on Thursday, 23 April 2020.

Wilsons Corporate Finance Limited acted as sole lead manager, bookrunner and underwriter to the Entitlement Offer.

The results of the Entitlement Offer highlight the recognition from shareholders of the long-term value in SomnoMed and a support for the initiatives of the Company.

Terry Flitcroft
Company Secretary
SomnoMed Limited

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep. SomnoDent® is the most comfortable and effective design and treatment solution for almost 525,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold in the Retail Entitlement Offer have not been, and will not be, registered under the United States Securities Act of 1933 (the **U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States.

Accordingly, the New Shares may not be offered or sold to persons in the United States, unless they have been registered under the U.S. Securities Act, or are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This announcement contains such statements that are subject to risk factors associated with an investment in SomnoMed.